Company Overview
eXoZymes, Inc. functions as a development stage biotechnology company dedicated to the creation of enzyme modules and cell-free exozyme biosolutions designed specifically for synthetic biology manufacturing operations. This enterprise operates within the broader Healthcare sector, specifically targeting the Biotechnology industry, which implies a focus on high-risk, high-reward scientific innovation rather than established consumer goods or services. The company's scale is defined by a market capitalization of $60.06M, a reported annual revenue of N/A, and an employee count of 31 individuals. These financial metrics collectively indicate that the entity operates with a modest market presence, suggesting that its valuation is driven primarily by potential future intellectual property and technological capabilities rather than current revenue generation or a large workforce.
Financial Health
The company reports a Net Income (TTM) of $-8,339,672 and an EBITDA of $-8,722,368, while Revenue (TTM) is listed as N/A, indicating that the firm is not yet generating sufficient commercial sales to offset its operational expenditures. The substantial gap between the non-existent revenue figure and the significant net loss reveals a cost structure dominated by research and development expenses and other overhead costs inherent to a development-stage biotechnology firm that has not yet achieved commercial product launch. Furthermore, the Free Cash Flow stands at $-3,585,291, which signifies that the company is burning cash to fund its operations and R&D initiatives, thereby limiting its immediate financial flexibility without external capital injections. Analysis of the three primary margins shows a Gross Margin of 0.0%, an Operating Margin of 0.0%, and a Profit Margin of 0.0%, indicating that the company has not yet achieved profitability at the gross, operating, or bottom-line levels due to its pre-revenue status. In terms of balance sheet composition, the firm holds $5.10M in cash against $1.32M in debt, resulting in a Debt to Equity ratio of 24.56, which suggests a conservative approach to leverage given the cash surplus, although the high ratio reflects the small equity base relative to liabilities. The Current Ratio is 4.53, a figure that indicates strong short-term liquidity and the ability to cover current liabilities with current assets, providing a buffer against immediate financial obligations. Finally, the Return on Equity is -940.7% and the Return on Assets is -99.8%, metrics that reveal management has not yet generated positive returns on capital deployed, a common characteristic of early-stage biotech companies where losses are incurred to build value.
Valuation Assessment
The Trailing P/E Ratio (TTM) and Forward P/E are both listed as N/A, which implies that traditional earnings-based valuation models are inapplicable because the company has not produced positive earnings over the trailing twelve months or has no forecasted earnings to support a forward multiple. The Price to Book ratio is 11.15, a figure that indicates the market is valuing the company at a significant premium over its book value, reflecting high expectations for future growth despite the current lack of earnings. The Price to Sales ratio is N/A and the EV/EBITDA is -6.44; the negative EV/EBITDA metric suggests that the company's enterprise value is being weighed against substantial negative earnings, a standard metric for unprofitable growth companies where valuation relies on revenue potential or asset backing rather than cash flow. The 52-Week High is $18.40 and the 52-Week Low is $7.08, meaning the current trading price sits somewhere within this historical range, subject to market sentiment regarding the company's pipeline progress. The Beta value is N/A, which indicates that there is insufficient historical data or market consistency to calculate the stock's volatility relative to the broader market, making it difficult to quantify systematic risk using standard beta metrics.
Growth & Income
The Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, reflecting the fact that the company is in a development stage where year-over-year comparison is not yet feasible or meaningful due to inconsistent reporting or lack of commercial revenue. Since the company does not pay dividends, the Dividend Yield is N/A and the Payout Ratio is 0.0%, confirming that the firm reinvests any available capital, including its cash reserves, directly back into research, development, and operational expansion rather than distributing income to shareholders. This reinvestment strategy is typical for biotechnology firms in the early phases of their lifecycle, where capital expenditure is prioritized to advance enzyme modules and biosolutions toward market readiness. The overall growth and income profile is characterized by a complete absence of current income generation or historical growth rates, positioning the stock as a speculative vehicle reliant on successful future commercialization rather than existing financial performance.